SGHT Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

5.570

Open

5.440

VWAP

5.41

Vol

220.65K

Mkt Cap

291.09M

Low

5.300

Amount

1.19M

EV/EBITDA(TTM)

Total Shares

54.41M

253.74M

EV/OCF(TTM)

P/S(TTM)

3.64

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.

Events Timeline

(ET)

2026-05-06

17:10:00

Sight Sciences Q1 Revenue $19.7M, Exceeds Expectations

2026-05-06

17:10:00

Sight Sciences Raises 2026 Revenue Guidance to $83M-$89M

2026-03-30 (ET)

2026-03-30

07:30:00

Sight Sciences Awarded $34M in Damages, Alcon Found Liable for Infringement

News

9.5

05-07seekingalpha

Sight Sciences Reports Strong Q1 2026 Earnings with Revenue Guidance Raise

9.5

05-06seekingalpha

Sight Sciences Q1 Earnings Beat Expectations with Revenue Guidance Raised

2.0

04-22Newsfilter

Sight Sciences Releases Annual Sustainability Report Highlighting Key Initiatives

7.0

03-30Newsfilter

Sight Sciences Prevails in Patent Infringement Case Against Alcon

6.0

03-30moomoo

SIGHT SCIENCES: 10% ROYALTY ON HYDRUS REVENUE GRANTED UNTIL NOVEMBER 10, 2028

7.0

03-30moomoo

SIGHT SCIENCES: $34 MILLION IN MONETARY DAMAGES AWARDED, ALONG WITH ADDITIONAL DAMAGES AND INTEREST, FOR PRIOR INFRINGEMENT

8 Analyst Rating

Wall Street analysts forecast SGHT stock price to rise

5 Buy

3 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

6.00

Averages

9.35

High

12.00

Current: 0.000

Low

6.00

Averages

9.35

High

12.00

Citi

Neutral

maintain

AI Analysis

2026-07-08

New

Reason

Citi

Price Target

AI Analysis

2026-07-08

New

maintain

Neutral

Reason

Citi raised the firm's price target on Sight Sciences to $6 from $5.15 and keeps a Neutral rating on the shares. For Q2 earnings season, given "the skittish trading environment," the firm prefers higher-quality medtech stocks that may be positioned for a catch-up trade, the analyst tells investors in a preview.

Citi

Neutral

maintain

2026-05-28

Reason

Citi

Price Target

2026-05-28

maintain

Neutral

Reason

Citi raised the firm's price target on Sight Sciences to $5.15 from $4.35 and keeps a Neutral rating on the shares. The firm updated models in the medical technology space post the Q1 reports. Citi believes fundamentals in the sector remain solid.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SGHT

Unlock Now

Valuation Metrics

The current forward P/E ratio for Sight Sciences Inc (SGHT.O) is 0.00, compared to its 5-year average forward P/E of -7.38. For a more detailed relative valuation and DCF analysis to assess Sight Sciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.38

Current PE

0.00

Overvalued PE

-2.82

Undervalued PE

-11.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.70

Current EV/EBITDA

-7.49

Overvalued EV/EBITDA

-0.01

Undervalued EV/EBITDA

-13.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.57

Current PS

3.08

Overvalued PS

11.10

Undervalued PS

0.05

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

market movers ready to brakeout

Intellectia · 14 candidates

Rsi Category: moderateRelative Vol: >= 1.80Week Price Change Pct: $3.00 - $15.00Support Resistance Relationship: PriceAroundResistance, PriceAroundUpperBollMonthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

NTLA

Intellia Therapeutics Inc

1.82B

POET

POET Technologies Inc

1.06B

NTR

Nutrien Ltd

36.44B

AMBP

Ardagh Metal Packaging SA

2.90B

SGRY

Surgery Partners Inc

2.05B

ALMU

Aeluma Inc

347.27M

Whales Holding SGHT

Long Focus Capital Management LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Sight Sciences Inc (SGHT) stock price today?

The current price of SGHT is 5.35 USD — it has decreased -2.37

What is Sight Sciences Inc (SGHT)'s business?

What is the price predicton of SGHT Stock?

Wall Street analysts forecast SGHT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGHT is9.35 USD with a low forecast of 6.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.